Ketosis in Type 2 Diabetics on SGLT-2 inhibitors
Research type
Research Study
Full title
Ketosis in Type 2 Diabetics on SGLT-2 inhibitors: A Prospective Observational Cohort Study
IRAS ID
205886
Contact name
Gowrie Balasubramaniam
Contact email
Sponsor organisation
Southend University Hospital
Clinicaltrials.gov Identifier
ISRCTN96827601, ISRCTN number
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Type 2 diabetes is an increasing problem worldwide. There is now a new type of treatment that has been shown to be effective in preventing serious complications of type 2 diabetes. The treatment is a medication that works by allowing your kidneys to pass sugar from the blood into the urine, thereby reducing the amount of sugar in the blood.
These drugs have been shown to be very good at controlling the blood sugar, helping to lose weight and may in fact help protect against heart disease. More and more people will probably be started on this treatment because of these benefits.
There have been some reports of a complication called ketoacidosis in people with type 2 diabetes on this treatment. Ketoacidosis commonly occurs in people with type 1 diabetes where there is no insulin available. The cells in the body cannot use sugar as energy and start breaking down fats, making a chemical called ketones as a by-product. High levels of ketones can cause a condition called acidosis when the blood becomes very acidic and this can be life-threatening. It does not normally occur in type 2 diabetes but may occur more frequently if people with type 2 diabetes are on this treatment.
We would like to do a study where we will check the levels of ketones in people with type 2 diabetes who are on the new treatment. We will do this when they are well, as they join the study, and also when they become unwell. We can then look to see if ketoacidosis is a common complications or a rare complication of this treatment.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
16/LO/1774
Date of REC Opinion
17 Oct 2016
REC opinion
Further Information Favourable Opinion